3篇
您的检索式：作者名="J.M. Alvarez"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Plasticity of Xyloglucan Composition in Bean (Phaseolus vulgaris)-Cultured Cells during Habituation and Dehabituation to Lethal Concentrations of Dichlobenil显示文摘被使熟习到的豆子房间在致命的集中成长(12 ? M ) 2,6-dichlorobenzonitrile (dichlobenil 或 DCB,一个纤维素生合成禁止者) 被知道减少了在他们的房间墙中的纤维素内容。Xyloglucan,它纤维素并且和它一定形成植物房间墙的主要装载网络,也被描述了在使熟习的房间减少,但是纤维素上的变化是否除它的丰富以外影响 xyloglucan 结构,有不分析。有 xyloglucan 特定的 endoglucanase (XEG ) 和 endocellulase 的破碎分析表明到 DCB 的使习惯在 xyloglucan 的好结构引起了一个变化,也就是,在 fucosyl 残余的减少沿着 glucan 脊梁属于 galactosylxylosyl 残余。在从媒介(dehabituated 房间) 的除草剂的移动以后, xyloglucan 恢复了它的 fucosyl 残余。另外,某 cello-oligosaccharides 能仅仅在使熟习的房间 XEG 和 endocellulase 消化的 xyloglucan 被检测,相应于与 hemicelluloses covalently 固定或一同沉淀的 glucan。这些结果证明房间墙的结构的灵活性部分地依靠 xyloglucan 作文的粘性并且开创新观点在这个领域里推进研究。 | A. Alonso-Simon L. Neumetzler R Garcia-Angulo A.E. Encina J.L. Acebes J.M. Alvarez T. Hayashi | 2010 | Molecular Plant2010，3，3： | 3 |
| 2 | Influence of nanosilica and a polycarboxylate ether superplasticizer on the performance of lime mortars显示文摘 | J.M. Fernández A. Duran I. Navarro-Blasco J. Lanas R. Sirera J.I. Alvarez | 2013 | Cement and Concrete Research2013，，： | 1 |
| 3 | 新型化疗药物KW-2170对复发卵巢上皮细胞癌的疗效和毒性显示文摘Objectives.:KW-2170 is a novel DNA intercalating agent whose mechanism of action is similar to doxorubicinHCl,yet is associated with less cardiac toxicity. The objective of this study was to evaluate the activity and toxicity of this novel chemotherapeutic agent in patients with recurrent ovarian carcinoma. Methods.:A prospective phase II trial was performed in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma and measurable disease. Patients could have platinum-sensitive or refractory disease and could have received any number of prior treatments. One treatment cycle consisted of KW-2170 administered at a dose of 18 mg/m2 weekly for 3 weeks followed by a 21-day rest period. Toxicity was assessed using the NCI Common Toxicity Criteria (Version 2.0),and dose reduction was allowed for significant toxicity. Response to therapy was assessed in patients who completed at least 2 cycles using RECIST criteria. Results.:A total of 28 patients were enrolled in this phase II trial at 5 separate centers. Of the 28 patients evaluated,all had stage III/IV disease at initial diagnosis. The median number of prior therapeutic regimens in these patients was 4 (range 1-8). The median number of KW-2170 cycles administered was 2 (range 1-5). Treatment-related toxicity in this heavily pretreated population was acceptable as only 6 patients (21%) had grade 3-4 neutropenia. Dose reductions occurred in 6 patients (21%) for grades 1-4 neutropenia,and no patient had febrile neutropenia. Four patients completed less than 1 cycle; 3 secondary to progressive disease,and one due to Gram-positive sepsis. Of patients receiving at least 2 full cycles,10 patients (55%) had stable disease with a median of 4.5 months (range 3-10) to disease progression. All other patients were removed from the study after 1-2 cycles of therapy with no significant clinical effect noted. Conclusions.:Although associated with relatively little toxicity,KW-2170 at the dose and schedule evaluated demonstrated little clinical activity in this heavily pretreated population of recurrent ovarian cancer patients. Whether KW-2170 would have greater clinical activity in a more treatment naive group of patients at an increased dose awaits clinical trial evaluation. | Estes J.M. Leath C.A. Williams S. R.D. Alvarez 马超 | 2006 | 世界核心医学期刊文摘(妇产科学分册)2006，0，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员